AB
ABDX.LSE Abingdon Health Plc
- Market cap
- GBX 41.3M
- P/E
- -
- P/B
- 6.41x
- ROE
- -34.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ABDX.LSE undervalued?
Graham numberThe Graham number of Abingdon Health Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abingdon Health Plc fundamental analysis
No fundamental analysis for Abingdon Health Plc yet.
Abingdon Health Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abingdon Health Plc
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices in the United Kingdom, Europe, the United States, Canada, and internationally. It operates through Contract Development, Contract Manufacturing, Product Sales, and Regulatory segments. The company also engages in manufacturing of lateral flow devices; and provision of support in meeting compliance requirements in international IVD and medical device markets. Its diagnostic products include PCRD: N…
Full company profileAbingdon Health Plc financial statements
Abingdon Health Plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.39M | 2.27M | 2.28M | 5.24M | 11.6M | 2.84M | 4.05M | 6.14M | 8.43M | 11.0M |
| Gross Profit | 1.06M | 1.34M | 1.57M | 4.09M | 3.39M | -5.23M | 1.40M | 3.68M | 3.13M | 5.18M |
| Operating Income | -2.40M | -4.70M | -1.40M | 217K | -5.52M | -12.1M | -3.85M | -1.37M | -4.03M | -2.86M |
| EBITDA | - | 8.00M | -1.10M | -2.84M | -6.07M | -20.0M | -2.81M | -916K | -3.12M | -2.13M |
| Net Income | -3.18M | 3.47M | -1.26M | -3.37M | -6.97M | -21.3M | -3.47M | -1.27M | -3.42M | -2.13M |
| EPS | - | 0.04 | -0.01 | -0.04 | -0.07 | -0.07 | -0.01 | 0.00 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 8.60M | 6.92M | 7.33M | 11.0M | 33.2M | 12.8M | 6.06M | 5.09M | 9.31M | 10.8M |
| Total Liabilities | 8.72M | 1.11M | 1.24M | 8.22M | 11.9M | 6.34M | 3.05M | 2.84M | 4.01M | 4.71M |
| Shareholders' Equity | -116K | 5.81M | 6.09M | 2.75M | 21.3M | 6.43M | 3.01M | 2.25M | 5.30M | 6.10M |
| Cash & Short-term Investments | 2.03M | 477K | 866K | 4.39M | 4.98M | 2.40M | 3.24M | 1.44M | 1.92M | 2.87M |
| Total Debt | 7.57M | 570K | 504K | 4.77M | 1.50M | 1.28M | 1.02M | 1.05M | 1.03M | 1.34M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.66M | -2.55M | -908K | 2.10M | -12.9M | -7.74M | 1.00M | -1.66M | -3.18M | -1.60M |
| Capital Expenditure | 669K | 359K | 96.2K | 1.65M | 7.25M | 760K | 157K | 41.0K | 327K | 190K |
| Free Cash Flow | - | -2.91M | -1.00M | 445K | -20.1M | -8.50M | 845K | -1.70M | -3.43M | -1.79M |
| Ratios | ||||||||||
| ROE | - | 59.7% | -20.7% | -122.7% | -32.7% | -330.6% | -115.3% | -56.5% | -64.4% | -34.9% |
| ROA | -37.0% | 50.1% | -17.2% | -30.8% | -21.0% | -166.5% | -57.2% | -25.0% | -36.7% | -19.7% |
| Net Profit Margin | -228.9% | 152.9% | -55.3% | -64.5% | -60.0% | -750.0% | -85.8% | -20.7% | -40.5% | -19.4% |
| Debt to Equity | - | 0.10x | 0.08x | 1.74x | 0.07x | 0.20x | 0.34x | 0.47x | 0.19x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Abingdon Health Plc dividends
Abingdon Health Plc has not paid dividends in the last 10 fiscal years.
Last stock split: 673:671 on Dec 2, 2021.
Who owns Abingdon Health Plc
- Insiders 30.43%
- Institutions 31.57%
- Public & others 38.00%
- Shares outstanding 253M
- Free float 170M
Abingdon Health Plc company profile
- Company name
- Abingdon Health Plc
- Ticker
- ABDX.LSE
- ISIN
- GB00BLF79J41
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 131
- Fiscal year end
- June
- Address
- York Biotech Campus, York, United Kingdom, YO41 1LZ
- Phone
- 44 19 0440 6050
- Website
- abingdonhealth.com
About Abingdon Health Plc
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices in the United Kingdom, Europe, the United States, Canada, and internationally. It operates through Contract Development, Contract Manufacturing, Product Sales, and Regulatory segments. The company also engages in manufacturing of lateral flow devices; and provision of support in meeting compliance requirements in international IVD and medical device markets. Its diagnostic products include PCRD: Nucleic acid lateral flow, a rapid, portable nucleic acid detection; Abingdon simply test, a consumer self-test supplied to retailers, pharmacies, and healthcare providers; Pocket Diagnostic, a rapid lateral flow for agritech, including plant health test; and Appdx, a patented smartphone reader software which turns a phone camera into an accurate lateral flow reader with secure data capture. In addition, the company provides analytical services comprising laboratory, clinical trials and CRO, and medical device bioburden and biocompatibility; and AI, software and digital health, regulatory affairs, quality management systems, consultancy, PRRC and outsourced support, technical documentation, and audit readiness and risk management services. Further, it offers regulatory and other consultancy services to businesses in the diagnostics and medtech sectors. Abingdon Health Plc was incorporated in 2008 and is based in York, the United Kingdom.
Abingdon Health Plc management
8- Dr. Christopher William HandExecutive Chairman · born 1961
- Mr. Thomas Edward HayesSecretary, CFO & Director · born 1976
- Mr. Mark JonesChief Operating Officer
- Ms. Nina GarrettChief Technical Officer
- Ms. Natalie ThrushChief of Staff
- Ms. Candice VendettuoliChief Delivery Officer
- Mr. Chris Henry Francis YatesChief Commercial Officer, President & Director of Abingdon Health USA Inc · born 1974
- Laura TowseController